Prediction of Prostate Cancer Progression Possible with Hyperspectral Imaging
Pittsburgh, PA, August 11, 2010 --(PR.com)-- A study conducted by scientists at ChemImage Corporation, in partnership with a well-known U.S. medical research and treatment center, revealed that Raman Molecular Imaging (RMI), a type of hyperspectral imaging, has potential in predicting the progression of prostate cancer.
Blinded samples from 38 patients with Gleason score 7 prostate cancer were evaluated using RMI, an emerging technology that combines digital imaging and molecular spectroscopy to analyze chemically different materials. Half of these patients progressed to a metastatic form of the disease, while the other half had no evidence of it after treatment.
RMI was successful in distinguishing the chemical differences of patients who progressed to the metastatic state in comparison to those who had no sign of the cancer.
"The results we’ve experienced thus far with RMI are encouraging," said John Maier, Vice President of Biomedical Research at ChemImage. "We plan on continuing this research on prostate cancer, as we investigate the application of RMI to other cancers such as lung and kidney."
Complete results of this study will be published in the August 11 issue of the British Journal of Urology International, an internationally distributed peer-reviewed journal focused on urology, in an article titled “Raman spectral imaging of prostate cancer: can Raman molecular imaging be used to augment standard histopathology?”
For more information regarding ChemImage’s work on prostate cancer, visit: http://www.chemimage.com/BJU.
If your organization would like to participate in future RMI research studies, contact John Maier at maier@chemimage.com.
About ChemImage
ChemImage Corporation, a leader in Hyperspectral Imaging technology (including Chemical and Molecular Imaging), provides instrumentation, software, contract services and expert consulting to government, industrial and academic organizations. The company’s proprietary, state-of-the-art Hyperspectral Imaging technology has many applications, including defense, security, pharmaceuticals, forensics and biomedical diagnostic research, which can reveal critical chemical and biological information from a variety of material systems.
ChemImage’s headquarters is located in Pittsburgh, Pennsylvania, where it houses research and development laboratories, as well as engineering and manufacturing facilities.
###
Blinded samples from 38 patients with Gleason score 7 prostate cancer were evaluated using RMI, an emerging technology that combines digital imaging and molecular spectroscopy to analyze chemically different materials. Half of these patients progressed to a metastatic form of the disease, while the other half had no evidence of it after treatment.
RMI was successful in distinguishing the chemical differences of patients who progressed to the metastatic state in comparison to those who had no sign of the cancer.
"The results we’ve experienced thus far with RMI are encouraging," said John Maier, Vice President of Biomedical Research at ChemImage. "We plan on continuing this research on prostate cancer, as we investigate the application of RMI to other cancers such as lung and kidney."
Complete results of this study will be published in the August 11 issue of the British Journal of Urology International, an internationally distributed peer-reviewed journal focused on urology, in an article titled “Raman spectral imaging of prostate cancer: can Raman molecular imaging be used to augment standard histopathology?”
For more information regarding ChemImage’s work on prostate cancer, visit: http://www.chemimage.com/BJU.
If your organization would like to participate in future RMI research studies, contact John Maier at maier@chemimage.com.
About ChemImage
ChemImage Corporation, a leader in Hyperspectral Imaging technology (including Chemical and Molecular Imaging), provides instrumentation, software, contract services and expert consulting to government, industrial and academic organizations. The company’s proprietary, state-of-the-art Hyperspectral Imaging technology has many applications, including defense, security, pharmaceuticals, forensics and biomedical diagnostic research, which can reveal critical chemical and biological information from a variety of material systems.
ChemImage’s headquarters is located in Pittsburgh, Pennsylvania, where it houses research and development laboratories, as well as engineering and manufacturing facilities.
###
Contact
ChemImage Corporation
Suzanne Cibotti
412-241-7335
http://www.chemimage.com/BJU
Suzanne Cibotti
412-241-7335
http://www.chemimage.com/BJU
Contact
Categories